Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Efficacy Of Pfizer's Paxlovid COVID Drug Crashes, According To New NIH-Funded Study

A new National Institutes of Health (NIH) funded study sheds new light on the waning effectiveness of Pfizer’s (NYSE: PFE) Paxlovid to prevent patient hospitalizations due to COVID.

Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga

Revive Therapeutics Data Access Plan Approved By The FDA; Partial Unblinded Data In Company Hands

Revive Therapeutics Ltd. (OTC: RVVTF) moved closer towards potential endpoint change in their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Fauci suffers COVID symptom rebound after course of Pfizer’s Paxlovid

Anthony Fauci, the chief medical adviser to President Joe Biden, suffered a rebound of COVID-19 symptoms after taking Pfizer Inc.’s antiviral Paxlovid.

Tribune News Service

European Commission defiant over Von der Leyen’s Pfizer texts

EU executive defends its right not to keep records of president’s messages after rebuke from ombudsman

The Guardian - UK

South Korea approves first homemade COVID-19 vaccine

Health officials in South Korea have approved the country's first domestically developed COVID-19 vaccine for people 18 years or older, adding another public health tool in the fight against a prolonged pandemic

The Independent UK

Detroit makes COVID vaccines available for children 6 months to 5 years

DETROIT — The city is providing COVID vaccines from Pfizer and Moderna for children ages 6 months up to 5 years of age, following emergency authorization from the federal Food and Drug Administration and approval from the state health department.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

COVID shots should get omicron-targeted update, FDA advisers say

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

Tribune News Service

US medical experts call for Omicron-specific Covid boosters

Washington (AFP) - A panel of US medical experts on Tuesday called for Omicron-specific boosters this fall, as anticipation mounts that Covid vaccines will be needed on an ongoing seasonal basis, as is the case for influenza.

AFP

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

The Conversation

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

Benzinga

From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid

A handful of small companies are working on long Covid treatments — sorely needed tools as the number of those afflicted grows.

Investors Business Daily

US grapples with whether to modify COVID vaccine for fall

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match the latest changes of the shape-shifting coronavirus

The Independent UK

US Covid-19 vaccine rollout for under-fives must overcome hesitancy

For many parents the availability of vaccination to the youngest age group is not before time but others plan to ‘wait and see’

The Guardian - US

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Pfizer’s omicron booster improves immune response, company says

Pfizer’s two omicron-focused booster vaccines massively improve a person’s immune response against the COVID variant, the company said Saturday.

The Street

Birth Control Stocks May Benefit From the Reversal of Roe v. Wade

The historic Supreme Court decision may force women to make different choices.

WEKU

Pfizer says its tweaked COVID-19 shots boost protection against the omicron variant

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

The Independent UK

Pfizer says tweaked COVID-19 shots boost omicron protection

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Misinformation will be rampant when it comes to COVID-19 shots for young children – here's what you can do to counter it

When the Centers for Disease Control and Prevention endorsed both the Pfizer-BioNTech and Moderna COVID-19 vaccines for all children ages 6 months to 5 years on June 18, 2022, it opened the door for nearly 20 million children to get vaccinated.

The Independent UK

Experts endorse Moderna COVID-19 shots for kids ages 6 to 17

An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17

The Philadelphia Inquirer

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

AFP

Pfizer sets sights on elimination of blinding disease trachoma by 2030

Kigali (AFP) - Pfizer on Thursday said it would extend until 2030 a drug donation programme aimed at eliminating trachoma, an eye disease responsible for blinding or visually impairing nearly two million people worldwide.

Tribune News Service

Editorial: Now let’s get Florida’s children vaccinated against COVID-19

America’s fight against COVID-19 reached another milestone Tuesday as the nation’s youngest children became eligible for the vaccine. This was a long-awaited moment that should bring relief to millions of American families. Now parents need to do their part by taking this opportunity to protect their children, their households and…

Benzinga

What Are Whales Doing With Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

Pfizer Strikes Deal With French Vaccine Maker -- Buy Or Sell?

Pharmaceutical company Pfizer (PFE) reported impressive first-quarter financials and is well-positioned to benefit from the equity subscription agreement with French vaccine maker Valneva. However, given the growing economic uncertainty, would it be worth adding the stock to your portfolio? Read more to find out.

1 … 43 44 45 46

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

332 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.